Zevra Therapeutics Inc (ZVRA)
8.66
+0.26
(+3.10%)
USD |
NASDAQ |
Nov 04, 13:01
Zevra Therapeutics Shareholders Equity (Quarterly): 32.48M for June 30, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 32.48M |
| March 31, 2024 | 48.82M |
| December 31, 2023 | 61.86M |
| September 30, 2023 | 67.47M |
| June 30, 2023 | 68.50M |
| March 31, 2023 | 71.40M |
| December 31, 2022 | 75.12M |
| September 30, 2022 | 93.79M |
| June 30, 2022 | 99.23M |
| March 31, 2022 | 121.50M |
| December 31, 2021 | 127.12M |
| September 30, 2021 | 131.74M |
| June 30, 2021 | 130.66M |
| March 31, 2021 | 84.25M |
| December 31, 2020 | -66.41M |
| September 30, 2020 | -62.33M |
| June 30, 2020 | -62.86M |
| March 31, 2020 | -68.68M |
| December 31, 2019 | -74.46M |
| September 30, 2019 | -70.62M |
| Date | Value |
|---|---|
| June 30, 2019 | -81.55M |
| March 31, 2019 | -74.84M |
| December 31, 2018 | -66.57M |
| September 30, 2018 | -95.34M |
| June 30, 2018 | -83.54M |
| March 31, 2018 | -79.68M |
| December 31, 2017 | -57.52M |
| September 30, 2017 | -48.10M |
| June 30, 2017 | -39.28M |
| March 31, 2017 | -33.93M |
| December 31, 2016 | -18.70M |
| September 30, 2016 | -9.802M |
| June 30, 2016 | 0.333M |
| March 31, 2016 | -11.48M |
| December 31, 2015 | -10.12M |
| September 30, 2015 | -5.746M |
| June 30, 2015 | 3.463M |
| March 31, 2015 | -54.35M |
| December 31, 2014 | -48.51M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-74.46M
Minimum
Dec 2019
131.74M
Maximum
Sep 2021
46.27M
Average
68.50M
Median
Jun 2023
Shareholders Equity (Quarterly) Benchmarks
| Vanda Pharmaceuticals Inc | 542.52M |
| BioCardia Inc | -1.961M |
| Xeris Biopharma Holdings Inc | -19.29M |
| Crinetics Pharmaceuticals Inc | 830.76M |
| Instil Bio Inc | 195.02M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 144.41M |
| Total Liabilities (Quarterly) | 111.93M |
| Debt to Equity Ratio | 1.796 |
| Current Ratio | 2.000 |
| Net Debt Paydown Yield | -4.41% |